A Randomized, Placebo-Controlled Trial of Citalopram for the Treatment of Major Depression in Children and Adolescents

Karen Dineen Wagner, M.D., Ph.D.
Adelaide S. Robb, M.D.
Robert L. Findling, M.D.
Jianqing Jin, Ph.D.
Marcelo M. Gutierrez, Ph.D.
William E. Heydorn, Ph.D.

Objective: Open-label trials with the selective serotonin reuptake inhibitor citalopram suggest that this agent is effective and safe for the treatment of depressive symptoms in children and adolescents. The current study investigated the efficacy and safety of citalopram compared with placebo in the treatment of pediatric patients with major depression.

Method: An 8-week, randomized, double-blind, placebo-controlled study compared the safety and efficacy of citalopram with placebo in the treatment of children (ages 7–11) and adolescents (ages 12–17) with major depressive disorder. Diagnosis was established with the Schedule for Affective Disorders and Schizophrenia for School-Age Children—Present and Lifetime Version. Patients (N=174) were treated initially with placebo or 20 mg/day of citalopram, with an option to increase the dose to 40 mg/day at week 4 if clinically indicated. The primary outcome measure was score on the Children's Depression Rating Scale—Revised; the response criterion was defined as a score of ≤28.

Results: The overall mean citalopram dose was approximately 24 mg/day. Mean Children's Depression Rating Scale—Revised scores decreased significantly more from baseline in the citalopram treatment group than in the placebo treatment group, beginning at week 1 and continuing at every observation point to the end of the study (effect size=2.9). The difference in response rate at week 8 between placebo (24%) and citalopram (36%) also was statistically significant. Citalopram treatment was well tolerated. Rates of discontinuation due to adverse events were comparable in the placebo and citalopram groups (5.9% versus 5.6%, respectively). Rhinitis, nausea, and abdominal pain were the only adverse events to occur with a frequency exceeding 10% in either treatment group.

Conclusions: In this population of children and adolescents, treatment with citalopram reduced depressive symptoms to a significantly greater extent than placebo treatment and was well tolerated.

(Am J Psychiatry 2004; 161:1079–1083)

Up to 5% of children and 8% of adolescents meet diagnostic criteria for depression, with the incidence of depression increasing markedly after puberty (1–4). The mean duration of pediatric depressive episodes is 9 months, and there is substantial risk for relapse (4, 5). Like depression in adults, pediatric depression is associated with significant social and functional impairment. School performance, peer relationships, and family functioning all are affected negatively in children and adolescents with depression (6), and risk of suicide is increased (7). Furthermore, depression in children and adolescents frequently continues into adulthood, resulting in considerable morbidity and mortality (8).

Although childhood depression is increasingly being recognized, few randomized, placebo-controlled trials of antidepressant pharmacotherapy have been reported in this population, and those that have appeared in the literature have had mixed results. For example, trials with tricyclic antidepressants have not demonstrated superiority over placebo (9). However, several recently published studies have suggested that selective serotonin reuptake inhibitors (SSRIs) may be effective and well tolerated in children and adolescents. In double-blind, placebo-controlled trials, fluoxetine (10, 11) and sertraline (12) have shown efficacy in the treatment of children and adolescents with major depression, as has paroxetine for the treatment of depressed adolescents (13). The use of SSRIs in children and adolescents has increased dramatically as a result of these trials, case reports, and open-label studies. Indeed, approximately 70% of family physicians and pediatricians in one mail survey reported prescribing SSRIs to children and adolescents with psychiatric disorders, including depression (14).

Citalopram, an SSRI shown to be effective in the treatment of depression in the adult population (15–17), appears well suited for use in children and adolescents because it has a favorable side effect profile, a low potential for drug-drug interactions, and is relatively safe in overdose (18, 19), which is of concern in this population (7).
Additionally, open-label trials and case reports suggest that citalopram is effective in younger patients (20, 21).

The objective of the current randomized, double-blind, placebo-controlled, flexible-dose study was to compare the efficacy and safety of citalopram with placebo in the treatment of children and adolescents with major depressive disorder.

Method

Study Population

This study was conducted at 21 hospital, academic, and research centers in the United States. Children (ages 7–11) and adolescents (ages 12–17) who met DSM-IV criteria for major depressive disorder and whose current episode of major depressive disorder was at least 4 weeks in duration at baseline were eligible for participation. The Schedule for Affective Disorders and Schizophrenia for School-Age Children—Present and Lifetime Version (K-SADS-PL) (22), a semistructured diagnostic interview, was used to establish that patients met DSM-IV criteria for major depressive disorder and to rule out other psychiatric diagnoses. A score of at least 40 on the Children’s Depression Rating Scale—Revised, in patients treated with citalopram versus placebo lead-in period, patients returned for a baseline visit to determine whether they remained eligible to participate. Eligible patients were then randomly assigned in double-blind fashion to 8 weeks of citalopram or placebo treatment. Citalopram was initiated at 20 mg/day, with the potential to increase the dose to 40 mg/day anytime after week 4 if deemed clinically necessary. Subsequent to week 4, the dose could be decreased to 20 mg/day for tolerability reasons. Evaluations were scheduled after 1, 2, 4, 6, and 8 weeks of double-blind treatment.

The primary outcome measure in this study was the change from baseline in score on the Children’s Depression Rating Scale—Revised at week 8 or upon termination. The Children’s Depression Rating Scale—Revised was administered at each study visit. Response was defined as a score ≤28 (indicating minimal residual symptoms). Secondary measures included Clinical Global Impression (CGI) improvement and severity ratings (25). At the final visit (week 8), a physical examination and laboratory tests were performed, and ECG results were obtained. Adverse events were spontaneously reported by patients or observed by investigators.

Statistical Analyses

Treatment differences in the primary efficacy outcome, baseline-to-endpoint change in score on the Children’s Depression Rating Scale—Revised, in patients treated with citalopram versus placebo were assessed using an analysis of covariance model, with treatment, study center, and age group as factors and the baseline score as covariate. A Cochran-Mantel-Haenszel test controlling for center and age group was applied for between-treatment comparison with respect to the response rate. These analyses were carried out using the last observation carried forward approach at week 8.

Results

A total of 178 patients (93 in the citalopram group and 85 in the placebo group) were randomly assigned to double-blind treatment. Four patients (three children and one adolescent), all randomly assigned to the citalopram group, were lost to follow-up and did not receive study medication. These patients were not included in the intent-to-treat analyses. Thus, the intent-to-treat population consisted of 89 patients (45 children and 44 adolescents) assigned to citalopram and 85 patients (38 children and 47 adolescents) assigned to placebo. Of these, 18 patients from each group discontinued double-blind treatment prematurely. Demographic and clinical characteristics of the patient population at baseline are summarized in Table 1. There were no significant differences in age,
FIGURE 1. Baseline-to-Endpoint Changes in Score on the Children's Depression Rating Scale—Revised in Children and Adolescents With Major Depressive Disorder Randomly Assigned to 8 Weeks of Double-Blind Treatment With Citalopram or Placebo

<table>
<thead>
<tr>
<th>Treatment Week</th>
<th>Placebo Group (N=85)</th>
<th>Citalopram Group (N=89)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Subjects receiving placebo</td>
<td>Subjects receiving citalopram</td>
</tr>
<tr>
<td>4</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>8</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Mean Change From Baseline in Score on Children's Depression Rating Scale Revisited

* p<0.05.  ** p<0.01.

---

TABLE 2. Treatment-Emergent Adverse Events in Children and Adolescents With Major Depressive Disorder Randomly Assigned to 8 Weeks of Double-Blind Treatment With Citalopram or Placebo

<table>
<thead>
<tr>
<th>Patients Experiencing Event</th>
<th>Placebo Group (N=85)</th>
<th>Citalopram Group (N=89)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rhinitis</td>
<td>5</td>
<td>12</td>
</tr>
<tr>
<td>Nausea</td>
<td>3</td>
<td>12</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>6</td>
<td>10</td>
</tr>
<tr>
<td>Influenza-like symptoms</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>Fatigue</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Back pain</td>
<td>3</td>
<td>5</td>
</tr>
</tbody>
</table>

*p<0.05. ** p<0.01.

---

gender, race, or weight between the placebo and citalopram groups. The mean age was 12.1 years in both treatment groups, and there were no differences between groups in the mean ages of children and adolescents. Additionally, responses to the K-SADS-PL (administered at the screening visit) indicated there were no clinically meaningful differences between the citalopram and placebo treatment groups in depression history. Ongoing secondary psychiatric disorders other than depression were reported in 23 patients, the most common diagnosis being dysthymia (citalopram group: 5.6%, placebo group: 1.2%) and enuresis (citalopram group: 4.5%, placebo group: 3.5%). A previous diagnosis of ADHD had been made in four citalopram-treated patients (4.5%) and one placebo-treated patient (1.2%); there were no reports of ongoing ADHD. Approximately 80% of the patients who participated in the study were experiencing a single episode of depression with a mean duration of 2 years. The mean duration of the current depressive episode was about 20 months. The age at onset was approximately 7 years for children and 12 years for the adolescent group. Twenty percent of the patients in the citalopram group and 18% of patients in the placebo group received previous antidepressant treatment, and approximately 15% of the patients in the citalopram group and 16% of the patients in the placebo group had a history of nonresponse to antidepressant treatment. Mean Children's Depression Rating Scale—Revised scores at baseline were 58.8 (SD=10.9) and 57.8 (SD=11.1) in the citalopram and placebo groups, respectively, indicative of moderately severe illness.

As noted in the Method section, investigators had the option to increase the dose of study medication to 40 mg/day citalopram or placebo equivalent any time after the week 4 visit. By the end of the study, medication dose had been increased in 53 placebo-treated patients (62.4%) and in 48 citalopram-treated patients (53.9%). In the citalopram group, the mean daily dose over the 8-week treatment period was 23.3 mg/day (SD=5.0) for the children and 24.4 mg/day (SD=5.0) for the adolescents.

Citalopram treatment showed statistically significant improvement compared with placebo on the Children's Depression Rating Scale—Revised as early as week 1 (F=6.58, df=1, 150, p<0.05), which persisted throughout the study (Figure 1). At week 8, the effect size on the primary outcome measure, Children's Depression Rating Scale—Revised (last observation carried forward), was 2.9. Additionally, at endpoint more citalopram-treated patients (36%) met the prospectively defined criterion for response than did placebo-treated patients (24%), a difference that was statistically significant (χ²=4.178, df=1, p<0.05). The proportion of patients with a CGI improvement rating ≤2 at week 8 was 47% for the citalopram group and 45% for the placebo group (last observation carried forward values). For the CGI severity rating, baseline values were 4.4 for the citalopram group and 4.3 for the placebo group, and endpoint values (last observation carried forward) were 3.1 for the citalopram group and 3.3 for the placebo group.

Citalopram treatment was well tolerated. All treatment-emergent adverse events that occurred with a frequency >5% in the citalopram group, and with an incidence in citalopram-treated patients that exceeded that in placebo-treated patients, are listed in Table 2. Of these, nausea, rhinitis, and abdominal pain were the only adverse events occurring in ≥10% of citalopram-treated patients. There were no reports of mania. The rate of discontinuation due to adverse events was comparable in the placebo and citalopram groups (5.9% versus 5.6%, respectively). The only adverse events that led to the discontinuation of more than one patient were aggravated depression (two placebo, no citalopram) and agitation (no placebo, two citalopram). No clinically significant ECG results, laboratory...
values, or weight changes were found. No serious adverse events were observed in any patient treated with citalopram in this study.

Discussion

This randomized, placebo-controlled, double-blind trial provides evidence that citalopram produces a statistically and clinically significant reduction in depressive symptoms in children and adolescents. Specifically, citalopram was superior to placebo on the primary efficacy measure, score on the Children's Depression Rating Scale—Revised, as early as week 1 with efficacy continuing throughout the trial. Reported adverse events were mild, and the rate of discontinuation due to adverse events was similar in the placebo and citalopram groups.

The results of this trial are in agreement with previous open-label trials (20) and case reports (21), which suggest that citalopram is efficacious and safe in children and adolescents with depression. In the current trial, citalopram-treated patients demonstrated significant improvement in depressive symptoms compared with placebo at week 1, an earlier time point than has been reported in other published trials of SSRIs in children and adolescents (10–12), although one placebo-controlled trial demonstrated significance for fluoxetine at week 1 (11). This is a potentially important observation, since therapeutic treatment options in these young patients remain limited, and early amelioration of symptoms may serve to enhance adherence to an adequate course of therapy.

In our study, the prospectively defined criterion of response was an endpoint score of ≤28 on the Children's Depression Rating Scale—Revised. In the Emslie et al. study of fluoxetine (11), a Children's Depression Rating Scale—Revised endpoint total score ≤28 was defined as remission. It is noteworthy, therefore, that the rates of response for citalopram (36%) were similar to the remission rates for fluoxetine (41%).

It is tempting to speculate that similar clinical results would be achieved in children and adolescents treated with the recently developed single isomer compound escitalopram, since the serotonin reuptake activity of citalopram is attributable to its S-isomer (26). This hypothesis is being tested in a multicenter, randomized, double-blind study of escitalopram in pediatric patients that is currently under way.

The mean citalopram dose for children and adolescents over the 8-week trial was approximately 25 mg/day, which is similar to the minimum dose shown to be effective in adults (27). There were no serious adverse events observed in the citalopram group. In fact, the overall adverse event profile was similar to that reported in adult trials, with no new or unexpected adverse events reported. Notably absent in this population of children and adolescents were dizziness and somnolence, two events frequently reported by adult patients (18). In this study, psychiatric adverse events were reported infrequently by patients randomly assigned to citalopram. For example, adverse events associated with behavioral activation (such as insomnia or agitation) were not prevalent in this trial.

The consistent and significant reduction in Children's Depression Rating Scale—Revised score in citalopram-treated patients compared with placebo-treated patients at weeks 1, 2, and 4 suggests that citalopram, 20 mg/day, is an effective dose in this population, since the citalopram dose was fixed throughout the first 4 weeks of the trial.

Of interest, early and sustained improvements in Children's Depression Rating Scale—Revised scores were observed with citalopram treatment in this study despite a relatively high rate of placebo response (which is common in pediatric trials with antidepressants). The study was not powered sufficiently to detect treatment differences by age group. Other limitations include the low number of patients with comorbid conditions and concomitant medication use, both of which are common in younger patients. It is not known whether the presence of comorbid psychiatric disorders such as ADHD would have affected the observed outcomes of this trial; however, the exclusion criteria employed produced a study population comparable to those of Emslie et al. (11) and Wagner et al. (12).

In conclusion, citalopram treatment significantly improved depressive symptoms compared with placebo within 1 week in this population of children and adolescents. No serious adverse events were reported, and the rate of discontinuation due to adverse events among citalopram-treated patients was comparable to that of placebo. These findings further support the use of citalopram in children and adolescents suffering from major depression.

References

3. Lewinsohn PM, Clarke GN, Seeley JR, Rohde P: Major depression in community adolescents: age at onset, episode dura-

http://ajp.psychiatryonline.org

Am J Psychiatry 161:6, June 2004


